$831.54
+34.09
(+4.27%)β²
Eli Lilly And Co is a pharmaceutical company that develops and sells prescription drugs in various therapeutic areas, including neuroscience, oncology, and endocrinology.
3.47%
Downside
Day's Volatility :5.24%
Upside
1.84%
32.46%
Downside
52 Weeks Volatility :42.25%
Upside
14.5%
Period | Eli Lilly And Company | Sector (Health Care) | S&P500 |
---|---|---|---|
3 Months | -6.74% | 0.1% | 12.2% |
6 Months | 7.78% | 4.8% | 15.0% |
1 Year | 40.62% | 19.6% | 37.9% |
3 Years | 217.36% | 12.8% | 28.0% |
Market Capitalization | 757.0B |
Book Value | $15.83 |
Dividend Share | 5.03 |
Dividend Yield | 0.67% |
Earnings Per Share (EPS) | 9.57 |
PE Ratio | 83.33 |
PEG Ratio | 0.75 |
Wall Street Target Price | 996.13 |
Profit Margin | 20.48% |
Operating Margin TTM | 39.77% |
Return On Assets TTM | 13.95% |
Return On Equity TTM | 65.32% |
Revenue TTM | 40.9B |
Revenue Per Share TTM | 45.37 |
Quarterly Revenue Growth YOY | 20.4% |
Gross Profit TTM | 21.9B |
EBITDA | 16.6B |
Diluted Eps TTM | 9.57 |
Quarterly Earnings Growth YOY | 0.68 |
EPS Estimate Current Year | 13.18 |
EPS Estimate Next Year | 23.13 |
EPS Estimate Current Quarter | 1.47 |
EPS Estimate Next Quarter | 5.47 |
What analysts predicted
Upside of 19.79%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 21.5B | β 6.03% |
Net Income | 3.2B | β 1683.54% |
Net Profit Margin | 15.04% | β 15.93% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 22.3B | β 3.84% |
Net Income | 4.6B | β 43.5% |
Net Profit Margin | 20.78% | β 5.74% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 24.5B | β 9.95% |
Net Income | 6.2B | β 33.55% |
Net Profit Margin | 25.24% | β 4.46% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 28.3B | β 15.4% |
Net Income | 5.6B | β 9.88% |
Net Profit Margin | 19.71% | β 5.53% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 28.5B | β 0.79% |
Net Income | 6.2B | β 11.88% |
Net Profit Margin | 21.88% | β 2.17% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 34.1B | β 19.56% |
Net Income | 5.2B | β 16.08% |
Net Profit Margin | 15.36% | β 6.52% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 8.3B | β 19.43% |
Net Income | 1.8B | β 31.1% |
Net Profit Margin | 21.21% | β 1.89% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 9.5B | β 14.27% |
Net Income | -57.4M | β 103.26% |
Net Profit Margin | -0.6% | β 21.81% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 9.4B | β 1.53% |
Net Income | 2.2B | β 3914.81% |
Net Profit Margin | 23.41% | β 24.01% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 8.8B | β 6.26% |
Net Income | 2.2B | β 2.43% |
Net Profit Margin | 25.58% | β 2.17% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 11.3B | β 28.91% |
Net Income | 3.0B | β 32.28% |
Net Profit Margin | 26.25% | β 0.67% |
Q3 FY24 | Q/Q Change | |
---|---|---|
Revenue | 11.4B | β 1.21% |
Net Income | 970.3M | β 67.3% |
Net Profit Margin | 8.48% | β 17.77% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 43.9B | β 2.38% |
Total Liabilities | 33.0B | β 0.94% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 39.3B | β 10.53% |
Total Liabilities | 36.6B | β 10.87% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 46.6B | β 18.7% |
Total Liabilities | 40.8B | β 11.54% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 48.8B | β 4.66% |
Total Liabilities | 39.7B | β 2.83% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 49.5B | β 1.4% |
Total Liabilities | 38.7B | β 2.36% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 64.0B | β 29.33% |
Total Liabilities | 53.1B | β 37.27% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 54.8B | β 3.11% |
Total Liabilities | 43.7B | β 4.29% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 57.9B | β 5.66% |
Total Liabilities | 46.6B | β 6.74% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 64.0B | β 10.52% |
Total Liabilities | 53.1B | β 14.02% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 63.9B | β 0.1% |
Total Liabilities | 51.0B | β 3.95% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 71.9B | β 12.4% |
Total Liabilities | 58.2B | β 14.09% |
Q3 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 75.6B | β 5.19% |
Total Liabilities | 61.3B | β 5.23% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 5.5B | β 1.62% |
Investing Cash Flow | 1.9B | β 150.38% |
Financing Cash Flow | -5.9B | β 4240.88% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 4.8B | β 12.45% |
Investing Cash Flow | -8.1B | β 524.08% |
Financing Cash Flow | -2.3B | β 60.63% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 6.5B | β 34.38% |
Investing Cash Flow | -2.3B | β 72.05% |
Financing Cash Flow | -3.1B | β 34.96% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 7.3B | β 11.71% |
Investing Cash Flow | -2.9B | β 26.94% |
Financing Cash Flow | -4.1B | β 31.69% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 7.1B | β 2.43% |
Investing Cash Flow | -3.8B | β 31.23% |
Financing Cash Flow | -5.4B | β 30.87% |
FY23 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 4.2B | β 40.15% |
Investing Cash Flow | -7.2B | β 90.08% |
Financing Cash Flow | 3.5B | β 164.65% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 631.9M | β 63.49% |
Investing Cash Flow | -459.1M | β 33.35% |
Financing Cash Flow | -1.0B | β 350.64% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 2.2B | β 246.49% |
Investing Cash Flow | -3.1B | β 570.99% |
Financing Cash Flow | 572.0M | β 155.35% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -311.9M | β 114.25% |
Investing Cash Flow | -2.9B | β 5.07% |
Financing Cash Flow | 3.5B | β 519.7% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 1.2B | β 473.84% |
Investing Cash Flow | -1.2B | β 59.73% |
Financing Cash Flow | -311.3M | β 108.78% |
Sell
Neutral
Buy
Eli Lilly And Company is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Eli Lilly And Company | -9.59% | 7.78% | 40.62% | 217.36% | 637.18% |
Johnson & Johnson | -3.22% | 3.75% | 5.46% | -4.33% | 17.8% |
Pfizer Inc. | -11.49% | -5.18% | -9.97% | -43.51% | -27.65% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Eli Lilly And Company | 83.33 | 83.33 | 0.75 | 13.18 | 0.65 | 0.14 | 0.01 | 15.83 |
Johnson & Johnson | 26.18 | 26.18 | 0.94 | 9.95 | 0.21 | 0.08 | 0.03 | 29.14 |
Pfizer Inc. | 36.83 | 36.61 | 0.72 | 2.93 | 0.05 | 0.03 | 0.06 | 16.29 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Eli Lilly And Company | Buy | $757.0B | 637.18% | 83.33 | 20.48% |
Johnson & Johnson | Buy | $380.1B | 17.8% | 26.18 | 16.74% |
Pfizer Inc. | Hold | $158.6B | -27.65% | 36.83 | 7.16% |
Insights on Eli Lilly And Company
Revenue is up for the last 3 quarters, 8.76B β 11.43B (in $), with an average increase of 11.8% per quarter
Netprofit is down for the last 2 quarters, 2.96B β 970.3M (in $), with an average decrease of 67.3% per quarter
Lilly Endowment Inc
Vanguard Group Inc
BlackRock Inc
PNC Financial Services Group Inc
State Street Corp
FMR Inc
In the quarter ending March,2024. Eli Lilly And Company has declared dividend of $1.30
Read MoreLilly (Eli) & Co. is an American-based multinational pharma company with offices in 18 countries. Its headquarters are situated in Indianapolis, Indiana, and it sells drugs in over 125 countries. Colonel Eli Lilly was a pharmaceutical chemist and American Civil War veteran who founded this company in 1876. It is traded as LLY in the New York Stock Exchange (NYSE). Lilly employs over 33,000 people and generated a revenue of over 22 billion USD as of 2019. The company is committed to researching and developing high-quality drugs for humankind's welfare by remaining true to its work. In 1876, this company produced the medicinal drug called quinine used in the treatment of Malaria. Among its many commendable innovations were gelatin-coating for the capsules & pills and sugar-coated pills that make them easier to swallow. It also developed various drugs for treating syphilis, rheumatism, eczema, and psoriasis in the early 1880s. A scientific journal asserted that the Lilly operation was the largest capsule factory in the world in 1917. In 1923, Lilly mass-produced the Insulin under the name βIletinβ used to treat diabetes in the US. Moreover, it also became the company to mass-produce Penicillin in the 1940s and started producing the Polio vaccine in the early 1950s. It acquired CoLucid in 20017 for 960mn USD and Armo Biosciences for 1.6bn USD in 2018. Also, it purchased the Aurora Kinase A, an inhibitor developer, for 575mn USD. It acquired multiple companies for developing and researching breakthroughs. The company aims to bring life-changing research to the community while performing voluntary & philanthropist operations worldwide. Currently Eli Lilly And Company has a market cap of $893.59 Billion. It has a P.E ratio of 121.71. The shares of Eli Lilly And Company are trading at $831.54. .
Organization | Eli Lilly And Company |
Employees | 43000 |
CEO | Mr. David A. Ricks |
Industry | Health Technology |